Biotech Archives - Page 104 of 795

2 minute read

Amedisys Offers Molecular Testing For Rapid And Accurate Infection Diagnosis In Collaboration With Patient Choice Laboratories

February 8, 8:35 AM

Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care in the home, is now offering advanced molecular testing to its care centers nationwide. This innovative collaboration with

AMED

2 minute read

Spyre Therapeutics Announces Three Abstracts Accepted For Presentation At The 19th Annual Congress Of The European Crohn’s And Colitis Organization

By Benzinga Newsdesk

February 8, 8:34 AM

Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine

SYRE

2 minute read

Analysts Boost Eli Lilly’s Forecast With High Hopes On Mounjaro, Zepbound Performance

By Vandana Singh

February 7, 3:49 PM

Eli Lilly's SYNERGY-NASH Phase 2 study results and positive market outlook drive BMO's raised price target to $865. Morgan Stanley remains bullish on Mounjaro/Zepbound launch. BofA Securities cites growth potential.

LLY

2 minute read

Investors’ Focus Around Amgen’s Obesity Drug Data Shadows Better Than Expected Q4 Earnings

By Vandana Singh

February 7, 3:36 PM

Amgen's Q4 2023: 15% net profit growth, $8.2 billion total revenues beat expectations. Prolia leads with 12% sales jump. Analysts' reactions and price targets.

AMGN

2 minute read

Why Is Gene Therapy-Focused REGENXBIO Stock Trading Higher Today?

By Vandana Singh

February 7, 1:59 PM

REGENXBIO's progress in Duchenne muscular dystrophy and MPS II treatment trials. Interim results for RGX-202 in Phase 1/2 trial and significant milestones achieved in Phase 1/2/3 trial with RGX-121.

RGNX

2 minute read

Catalent’s Bloomington Plant Making Novo Nordisk’s Obesity Drug Faces FDA Scrutiny Regarding Drug Manufacturing Concerns

By Vandana Singh

February 7, 1:02 PM

Novo Nordisk faces manufacturing challenges and drug shortages for diabetes and weight loss drugs, impacting Wegovy and Ozempic.

CTLT

3 minute read

REGENXBIO Announces Pivotal Trial Of RGX-121 For The Treatment Of MPS II Achieves Primary Endpoint

By Benzinga Newsdesk

February 7, 12:42 PM

Results support BLA submission in 2024 using the accelerated approval pathwayPrimary endpoint of patients achieving reduction in CSF biomarker of MPS II disease was met with statistical significance (p value of

RGNX

1 minute read

Why Alzheimers-Drug Developer Cassava Sciences Stock Is Trending

By Erica Kollmann

February 7, 12:15 PM

The top-line results showed no decline in cognition scores in patients with mild Alzheimer's disease who received simufilam continuously for 24 months. "We're fighting Alzheimer's disease by testing simufilam, a new type of drug that has a completely different mechanism of action from monoclonal antibody drug treatments," said Remi Barbier, CEO of Cassava.

SAVA

2 minute read

Immix Biopharma Awarded European Union Orphan Drug Designation For NXC-201 In AL Amyloidosis

By Benzinga Newsdesk

February 7, 10:41 AM

European Orphan Drug Designation ("ODD") qualifies NXC-201 for:10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for EU protocol assistance,

IMMX

2 minute read

Altamira Therapeutics’ Peptide-Based Delivery Platform Shown To Enhance Potency Of Commonly Used Gene Delivery Method Published In The Journal Of Integrative Medicine Titled, “Melittin Analog P5RHH Enhances Recombinant Adeno-Associated Virus Transducti…

By Benzinga Newsdesk

February 7, 9:48 AM

Independent peer-reviewed study shows enhanced cell transduction with adeno-associated virus (AAV) vectors, commonly used in gene therapy, when integrating Altamira's peptide-based delivery technology

CYTO